Article with exploratory alkylator-refractory subgroup analysis from Oncopeptides’ OCEAN study observing longer PFS and OS in melflufen vs. pomalidomide published in European Journal of Haematology
November 17, 2023
A new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, has been published in the European Journal of Haematology, an international journal for communication of research in hematology. The results further demonstrate efficacy and consistent safety profile in patients with alkylator-refractory disease.
Read more
Oncopeptides selected to present additional data from OCEAN study at the American Society of Hematology meeting
November 13, 2023
Oncopeptides announces that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12.
Read more
Oncopeptides publishes article in the Journal of Clinical Pharmacology
October 23, 2023
A new article on the Phamacokinetics and metabolism of melflufen, marketed in Europe as Pepaxti, in patients with Relapsed Refractory Multiple Myeloma was recently published in the Journal of Clinical Pharmacology, a journal designed to provide physicians, pharmacists, scientists and drug developers a forum to present research in all aspects of Clinical Pharmacology.
Read more
Oncopeptides publishes article on NK cell engagers in New Biotechnology
September 12, 2023
A new article, describing a set of affibody-based NK cell engagers using B cell maturation antigen (BCMA) as a model antigen for targeting of multiple myeloma, has been published online ahead of the November issue of New Biotechnology, the official journal of the European Federation of Biotechnology (EFB). Among the highlights of the article, dual engagers are found effective in activating resting NK cells and inducing a BCMA-dependent killing of MM cells.
Read more
Oncopeptides publishes two articles with results from ANCHOR and LIGHTHOUSE studies in Haematologica
September 4, 2023
Stockholm – September 4, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that two new articles with scientific data on melflufen, marketed in Europe as Pepaxti, has been published in Haematologica, a publication reporting on important findings...
Read more